Global Viral Vaccines Market Growth 2023-2029

Global Viral Vaccines Market Growth 2023-2029

LPI (LP Information)' newest research report, the “Viral Vaccines Industry Forecast” looks at past sales and reviews total world Viral Vaccines sales in 2022, providing a comprehensive analysis by region and market sector of projected Viral Vaccines sales for 2023 through 2029. With Viral Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vaccines industry.

This Insight Report provides a comprehensive analysis of the global Viral Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Viral Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Viral Vaccines market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vaccines and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vaccines.

The global Viral Vaccines market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Viral Vaccines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Viral Vaccines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Viral Vaccines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Viral Vaccines players cover GSK, Merck, Novartis, Pfizer, Sanofi, Bayer, Zoetis, AstraZeneca and Johnson, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vaccines market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Attenuated Vaccine
Inactivated Vaccine

Segmentation by application
Hospital
Pharmaceutical Factory
Research Institute
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GSK
Merck
Novartis
Pfizer
Sanofi
Bayer
Zoetis
AstraZeneca
Johnson
CSL

Key Questions Addressed in this Report

What is the 10-year outlook for the global Viral Vaccines market?

What factors are driving Viral Vaccines market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Viral Vaccines market opportunities vary by end market size?

How does Viral Vaccines break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.